L32 - Hemostasis Testing Modalities

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/47

encourage image

There's no tags or description

Looks like no tags are added yet.

48 Terms

1
New cards

What are the Main Causes of Abnormal Bleeding?

  1. Trauma

  2. Thrombocytopenia

  3. Platelet dysfunction

  4. Vasculopathy

  5. Coagulation factor disorders.


2
New cards

What are the Key Pre-Analytical Requirements for Coagulation Testing?

  • Use citrated blood (blue-top tube) with a 9:1 blood-to-citrate ratio

  • Perform clean venipuncture

  • Avoid platelet activation or tissue factor contamination


3
New cards

Why is Sodium Citrate Used for Coagulation Testing?

It reversibly binds calcium to prevent clotting

  • Calcium is added back during laboratory testing


4
New cards

How Should Plasma Samples Be Processed for Coagulation Testing?

  1. Separate plasma within 1 hour

  2. Test within 4 hours when possible, and freeze separated plasma if delayed

  3. Follow laboratory-specific instructions


5
New cards

Which Tests Evaluate Primary Hemostasis?

  1. CBC/platelet count

  2. Buccal mucosal bleeding time (BMBT)

  3. Aggregometry

  4. PFA-100

  5. von Willebrand factor testing

  6. Genetic testing,

  7. Specialized platelet function assays


6
New cards

What are the Limitations of Buccal Mucosal Bleeding Time (BMBT)?

It is easy to perform but variable and relatively insensitive

  • Results are affected by platelet number and function.


7
New cards

What is the General Principle of Clotting-Time Assays?

Add coagulation activators, calcium, and phospholipids as needed, then measure the time until clot formation using visual, mechanical, or optical detection

8
New cards

What is Activated Clotting Time (ACT), and How is It Performed?

A whole-blood test using an intrinsic-pathway activator tube incubated at 37°C

  • Clot formation is detected visually


9
New cards

What are the Normal ACT Reference Intervals for Dogs and Cats?

  • Dogs: 55–80 seconds

  • Cats: 55–85 second

  • Reference intervals depend on the method.


10
New cards

What Does a Prolonged ACT Indicate?

Severe intrinsic or common pathway factor deficiencies or severe thrombocytopenia

  • ACT is relatively insensitive


<p><span style="color: red;"><strong>Severe <em><u>intrinsic or common pathway</u></em> factor deficiencies</strong></span> or <span style="color: red;"><strong>severe thrombocytopenia</strong></span></p><ul><li><p>ACT is relatively insensitive</p></li></ul><p></p>
11
New cards

What is Activated Partial Thromboplastin Time (aPTT), and How is It Performed?

A citrated plasma test using an intrinsic-pathway activator, phospholipids, and calcium to measure clotting time

12
New cards

What Does a Prolonged aPTT Indicate?

Deficiency or dysfunction of intrinsic or common pathway factors

  • It is more sensitive than ACT and is not prolonged by thrombocytopenia alone


13
New cards

What is Prothrombin Time (PT), and How is It Performed?

A citrated plasma test using tissue factor, phospholipids, and calcium to activate the extrinsic pathway and measure clotting time

14
New cards

What Does a Prolonged PT Indicate?

Deficiency or dysfunction of extrinsic or common pathway factors

  • It is not prolonged by thrombocytopenia alone


15
New cards

How Do ACT, aPTT, and PT Differ?

ACT:

  • Intrinsic/common pathways

  • Whole blood

  • Relatively insensitive

  • Affected by severe thrombocytopenia

aPTT:

  • Intrinsic/common pathways

  • Citrated plasma

  • More sensitive

  • Unaffected by thrombocytopenia

PT:

  • Extrinsic/common pathways

  • Citrated plasma

  • Unaffected by thrombocytopenia.


16
New cards

How are PT and aPTT Results Interpreted Together?

  • Prolonged aPTT only → intrinsic pathway abnormality

  • Prolonged PT only → extrinsic pathway abnormality

  • Both prolonged → common pathway or multiple factor abnormalities


17
New cards

What is INR, and What is Its Purpose?

International normalized ratio

  • A unitless ratio used to standardize PT results across laboratories


18
New cards

What is PIVKA, and What Does the Veterinary PIVKA Test Evaluate?

Proteins induced by vitamin K antagonism or absence

  • Veterinary testing uses a modified PT-based assay to assess reduced activity of factors II, VII, and X

  • It does not directly measure PIVKA proteins


19
New cards

Which Coagulation Factors Require Vitamin K?

Factors II, VII, IX, and X

  • Vitamin K is required for their functional γ-carboxylation


20
New cards

What is Thrombin Time (TT/TCT), and What Does It Evaluate?

Thrombin is added to citrated plasma to measure fibrinogen conversion into fibrin

  • Abnormalities include dysfibrinogenemia and fibrin polymerization inhibitors


21
New cards

What is the Clauss Method for Measuring Fibrinogen?

A modified thrombin time assay that measures functional fibrinogen concentration

  • Preferred over heat precipitation


22
New cards

What is the Russell Viper Venom Test (RVVT)?

  • A citrated plasma assay using Russell's viper venom to activate factors X and V

  • Sensitive to antiphospholipid antibodies and rarely used in veterinary medicine


23
New cards

What is Viscoelastic Testing, and Which Methods are Used?

A global assessment of clot initiation, formation, strength, and breakdown over time

  • Methods include TEG, ROTEM, and Sonoclot.


24
New cards

What is the Main Advantage and Limitation of Viscoelastic Testing?

It evaluates multiple stages of clot development and fibrinolysis, but the test system lacks endothelial cells.

25
New cards

What Do the Main TEG/ROTEM Parameters Measure?

  • R/CT: time to clot initiation

  • K/CFT and α-angle: rate of clot formation

  • MA/MCF: maximum clot strength

  • LY30/LY60: clot breakdown


26
New cards

What Viscoelastic Findings Suggest Hypercoagulability vs. Hypocoagulability?

  • Hypercoagulability: shorter R/CT and K/CFT, increased α-angle and clot strength

  • Hypocoagulability: prolonged R/CT and K/CFT, decreased α-angle and clot strength


<ul><li><p><strong>Hypercoagulability:</strong> <span style="color: blue;">shorter R/CT and K/CFT,</span><span style="color: green;"> </span><span style="color: blue;"><strong><mark data-color="blue" style="background-color: blue; color: inherit;">increased α-angle and clot strength</mark></strong></span></p></li><li><p><strong>Hypocoagulability:</strong> <span style="color: red;">prolonged R/CT and K/CFT, <strong><mark data-color="red" style="background-color: red; color: inherit;">decreased α-angle and clot strength</mark></strong></span></p></li></ul><p></p>
27
New cards

How is Increased Fibrinolysis Identified with Viscoelastic Testing?

Increased clot breakdown on the tracing and increased lysis measurements

  • Adding tPA can improve detection of fibrinolysis.


28
New cards

How are Specific Coagulation Factor Activities Measured?

Specialized laboratories use modified PT/aPTT assays with factor-deficient plasma or chromogenic assays

  • Results are reported as percentage activity


29
New cards

What is the Main Mechanism of Fibrinolysis?

tPA converts plasminogen into plasmin → which degrades fibrin and fibrinogen into degradation products

<p><strong>tPA converts plasminogen into plasmin</strong> → <span style="color: red;"><strong><mark data-color="yellow" style="background-color: yellow; color: inherit;">which degrades fibrin and fibrinogen into degradation products</mark></strong></span></p>
30
New cards

How is Fibrinolysis Regulated?

  1. PAIs inhibit plasminogen activation

  2. α2-antiplasmin and α2-macroglobulin inhibit free plasmin

  3. TAFI limits fibrinolysis


<ol><li><p><strong>PAIs inhibit plasminogen activation</strong></p></li><li><p><strong>α2-antiplasmin and α2-macroglobulin inhibit free plasmin</strong></p></li><li><p><strong>TAFI limits fibrinolysis</strong></p></li></ol><p></p>
31
New cards

What are Fibrin/Fibrinogen Degradation Products (FDPs)?

Products of fibrinogen and fibrin breakdown, measured by immunoassays

  • Elevations may reflect increased fibrinolysis, fibrinogenolysis, or decreased clearance


32
New cards

What are D-Dimers, and What Do They Indicate?

Products specifically generated from degradation of cross-linked fibrin → indicating fibrin formation followed by breakdown

33
New cards

How Do FDPs and D-Dimers Differ?

  • FDPs: indicate degradation of fibrinogen or fibrin

    • Not specific for cross-linked fibrin

  • D-dimers: specifically indicate degradation of cross-linked fibrin


<ul><li><p><strong>FDPs:</strong> indicate degradation of <span style="color: red;"><em>fibrinogen or fibrin</em></span></p><ul><li><p>Not specific for cross-linked fibrin</p></li></ul></li><li><p><strong>D-dimers: </strong>specifically indicate degradation of <span style="color: red;"><em>cross-linked fibrin</em></span></p></li></ul><p></p>
34
New cards

How is Antithrombin (AT) Activity Measured?

A functional chromogenic assay measures inhibition of added thrombin or factor Xa

  • Greater AT activity produces less color


35
New cards

What are the Main Causes of Decreased Antithrombin Activity?

  1. Decreased production

  2. Increased loss

  3. Consumption during excessive coagulation


36
New cards

How is Protein C Activity Measured, and What Can Alter It?

A functional chromogenic assay reported as percentage activity

  • Changes may reflect impaired production, vitamin K antagonism, or altered activation


37
New cards
  • QUESTION: A 5 month old MI Yorkshire Terrier, presented to your clinics with a presenting complaint of lameness and subcutaneous hematoma. You ran a coagulation panel which indicated normal platelet count, PTT-24 sec (RI 8.5-15.5) sec, PT-12.3 sec (RI 11-15.5), TCT 6 sec (RI 5-9).

  • Which of the following coagulation factors is most likely to be deficient?

A. Factor 5 (V)

B. Factor 7 (VII)

C. Factor 8 (VIII)

D. Factor 1 (fibrinogen)

ANSWER → C. Factor VIII

  • Prolonged PTT indicates an intrinsic or common pathway abnormality.

  • Normal PT makes a common pathway deficiency less likely.

  • Normal TCT suggests that the final fibrinogen-to-fibrin step is functioning.

  • Factor VIII belongs to the intrinsic pathway.

  • Key takeaway: Isolated prolonged PTT → suspect an intrinsic pathway factor deficiency (VIII, IX, XI, or XII).


38
New cards

QUESTION: What is the most likely etiology of Skip’s coagulopathy?

A. Factor 8 deficiency (Hemophilia A)

B. Factor 9 deficiency (Hemophilia B)

C. Immune mediated thrombocytopenia

D. Vitamin K antagonism (rodenticide toxicity)

ANSWER → D. Vitamin K antagonism (rodenticide toxicity)

  • The professor explicitly explains that Skip's severe anemia and hypoproteinemia suggest acute hemorrhage. Both PT and PTT are markedly prolonged, indicating abnormalities affecting multiple coagulation pathways.

  • Vitamin K antagonism impairs the activity of factors II, VII, IX, and X.

  • Key takeaway: Prolonged PT + prolonged PTT, with severe hemorrhage, should raise suspicion for vitamin K antagonism.


39
New cards

QUESTION: 7 year old MC Lab presented for  lethargy, increased respiratory rate and effort. Lab work shows thrombocytopenia (22K), prolonged PT (>120 sec) and PTT (>140 sec), decreased fibrinogen (<50 mg/dl), decreased AT activity (30%) and increased D-dimer (1056 ng/ml). Liver values on serum biochemistry are unremarkable.

A. Consumption

B. Vitamin K antagonism

C. Decreased production

D. Loss via intestinal hemorrhage

ANSWER → A. Consumption

  • Widespread coagulation activation consumes platelets, factors, fibrinogen, and antithrombin while generating cross-linked fibrin that undergoes breakdown.

  • Meanwhile, increased D-dimers indicate that cross-linked fibrin is being formed and broken down.

  • Key takeaway: Thrombocytopenia + prolonged PT/PTT + decreased fibrinogen + decreased antithrombin + increased D-dimers suggests a consumptive coagulopathy.


40
New cards

What is the Recommended Initial Hemostasis Testing Panel, and What is Its Main Limitation?

Platelet count, PT, aPTT, fibrinogen concentration, and D-dimers

  • Hypercoagulability is generally harder to detect than hypocoagulability.


41
New cards

TABLE 1. Hemostasis Tests: What Does Each Test Evaluate?

Test

Evaluates

Main Purpose

Platelet count

Primary hemostasis

Detect thrombocytopenia

BMBT

Primary hemostasis

Assess platelet plug formation

ACT

Intrinsic + common pathways

Screen for severe coagulation abnormalities

aPTT

Intrinsic + common pathways

Detect intrinsic/common factor abnormalities

PT

Extrinsic + common pathways

Detect extrinsic/common factor abnormalities

TT/TCT

Fibrinogen → fibrin

Evaluate fibrin formation

Clauss fibrinogen

Functional fibrinogen

Measure fibrinogen concentration

TEG/ROTEM

Global hemostasis

Assess clot formation, strength, and breakdown

FDPs

Fibrin/fibrinogen breakdown

Detect increased degradation products

D-dimer

Cross-linked fibrin breakdown

Detect fibrin formation followed by degradation

AT activity

Natural anticoagulation

Assess antithrombin function

Protein C activity

Natural anticoagulation

Assess protein C function

Key concept: Different assays evaluate different parts of hemostasis. No single test identifies every bleeding or thrombotic disorder.

42
New cards

TABLE 2. ACT vs. aPTT vs. PT

Feature

ACT

aPTT

PT

Sample

Whole blood

Citrated plasma

Citrated plasma

Pathway

Intrinsic + common

Intrinsic + common

Extrinsic + common

Activator

Contact activator

Contact activator

Tissue factor

Calcium added?

No, typically

Yes

Yes

Sensitivity

Relatively low

Higher than ACT

Sensitive to extrinsic pathway abnormalities

Severe thrombocytopenia affects result?

Yes

No

No

Main use

Rapid screening

Factor abnormalities

Factor abnormalities

Memory trick:

  • aPTT = Inside (intrinsic pathway).

  • PT = Tissue factor (extrinsic pathway).

  • ACT = A Crude Test (less sensitive than aPTT).


43
New cards

TABLE 3. Interpreting PT and aPTT Together

PT

aPTT

Interpretation

Possible Factor Abnormalities

Normal

Normal

No detectable abnormality in these assays

Mild deficiencies and platelet disorders still possible

Normal

Prolonged

Intrinsic pathway

VIII, IX, XI, XII

Prolonged

Normal

Extrinsic pathway

VII

Prolonged

Prolonged

Common pathway or multiple factors

X, V, II, I or multiple deficiencies

Important: A prolonged clotting time means the sample takes longer to form a clot. It does not automatically tell you which specific factor is deficient.

44
New cards

TABLE 4. Fibrinolysis Testing: FDPs vs. D-Dimers

Feature

FDPs

D-Dimers

What is detected?

Fibrinogen and fibrin degradation products

Cross-linked fibrin degradation products

Sample

Usually citrated plasma

Citrated plasma

Method

Immunoassay, commonly latex agglutination

Immunoassay, commonly latex agglutination

Reported units

µg/mL

ng/mL

Increased results suggest

Increased fibrinolysis, fibrinogenolysis, or decreased clearance

Increased cross-linked fibrin breakdown or decreased clearance

Specific for cross-linked fibrin?

No

Yes

Memory trick:

  • FDP = Fibrin OR fibrinogen degradation.

  • D-dimer = Degradation of cross-linked fibrin.

    • D-dimers therefore provide more specific evidence that a stabilized fibrin clot was formed and subsequently broken down.


45
New cards

TABLE 5. Viscoelastic Testing (TEG vs. ROTEM)

Parameter

TEG

ROTEM

Hypercoagulable

Hypocoagulable

Clot initiation

R

CT

Shortened

Prolonged

Clot formation rate

K, α-angle

CFT, α-angle

Shorter K/CFT, higher α

Longer K/CFT, lower α

Clot strength

MA, G

MCF

Increased

Decreased

Clot breakdown

LY30/LY60

CLI30/CLI60

Assesses fibrinolysis separately

Assesses fibrinolysis separately

Key concept:

  • Unlike PT and aPTT, which measure time until clot formation

  • TEG/ROTEM assess the clot's development, strength, and breakdown over time


46
New cards

TABLE 6. Specialized Assays and Endogenous Anticoagulants

Assay

Method

What It Evaluates

PIVKA

Modified PT-based assay

Reduced activity of vitamin K-dependent factors II, VII, X

TT/TCT

Add thrombin to citrated plasma

Fibrinogen conversion to fibrin

Clauss fibrinogen

Modified thrombin time

Functional fibrinogen concentration

RVVT

Russell's viper venom activates factors X and V

Coagulation activity; sensitive to antiphospholipid antibodies

Specific factor activity

Modified PT/aPTT or chromogenic assays

Activity of an individual coagulation factor

Antithrombin activity

Functional chromogenic assay

Inhibition of thrombin or factor Xa

Protein C activity

Functional chromogenic assay

Protein C anticoagulant activity



47
New cards

Causes of Decreased Anticoagulant Activity

Anticoagulant

Possible Causes of Decreased Activity

Antithrombin

Decreased production, increased loss, consumption

Protein C

Decreased production, vitamin K antagonism, altered activation

Important: In the antithrombin chromogenic assay, greater AT activity means more inhibition of the added protease and therefore less color production

48
New cards

TABLE 7. Clinical Interpretation of Hemostasis Results

Clinical Findings

Interpretation

Example

Prolonged aPTT, normal PT and TCT

Intrinsic factor deficiency

Factor VIII deficiency (hemophilia A)

Prolonged PT, normal aPTT

Extrinsic factor abnormality

Factor VII deficiency

Prolonged PT and aPTT with severe hemorrhage

Multiple coagulation factor deficiencies

Vitamin K antagonism

Thrombocytopenia + prolonged PT/aPTT + low fibrinogen + low AT + high D-dimers

Consumptive coagulopathy

Widespread coagulation activation

Increased D-dimers

Cross-linked fibrin formation and breakdown

Increased fibrin turnover

Short R/CT + high MA/MCF

Hypercoagulable viscoelastic pattern

Increased clot strength

Important distinction: These patterns suggest particular mechanisms, but diagnosis requires the patient's history, examination, and additional laboratory findings.